Business Description
Galera Therapeutics Inc
NAICS : 325412
SIC : 2833
ISIN : US36338D1081
Share Class Description:
GRTXD: Ordinary SharesTotal Employee Number:
3Description
Galera Therapeutics Inc is a biopharmaceutical company that historically was focused on developing a portfolio of small-molecule superoxide dismutase (SOD) mimetics to improve radiotherapy in cancer, mainly by reducing one of the common side effects of radiotherapy, severe oral mucositis (SOM). Superoxide Dismutase Mimetics: excess superoxide from cancer, autoimmune diseases, or therapies like radiotherapy causes oxidative damage. Galera's SOD mimetics, avasopasem and rucosopasem, mimic natural enzymes to convert superoxide into hydrogen peroxide, reducing oxidative stress. Avasopasem is in trials for hormone-resistant advance breast cancer. Nitric oxide (NO) promotes tumor growth, angiogenesis, metastasis, and immune evasion.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.82 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 4/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 68 | |||||
3-Year EPS without NRI Growth Rate | 26 | |||||
3-Year FCF Growth Rate | 66.3 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 25.51 | |||||
9-Day RSI | 34.15 | |||||
14-Day RSI | 38.95 | |||||
3-1 Month Momentum % | 118.45 | |||||
6-1 Month Momentum % | 267 | |||||
12-1 Month Momentum % | 239.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.31 | |||||
Quick Ratio | 5.31 | |||||
Cash Ratio | 4.82 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -38.1 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | Neg. Equity | |||||
ROA % | 2323.52 | |||||
ROIC % | -2280.83 | |||||
3-Year ROIIC % | -563.81 | |||||
ROC (Joel Greenblatt) % | -2577.08 | |||||
ROCE % | -101.08 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 0.12 | |||||
Price-to-Owner-Earnings | 0.05 | |||||
PB Ratio | 8.16 | |||||
Price-to-Tangible-Book | 8.16 | |||||
EV-to-EBIT | -2.17 | |||||
EV-to-EBITDA | -2.17 | |||||
EV-to-Forward-Revenue | 8.52 | |||||
EV-to-FCF | -2.65 | |||||
| Price-to-Net-Current-Asset-Value | 9.48 | |||||
| Price-to-Net-Cash | 1.36 | |||||
Earnings Yield (Greenblatt) % | -46.08 | |||||
FCF Yield % | -28.66 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:GRTXD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Galera Therapeutics Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | 128 | ||
| Beta | 4.2817 | ||
| 3-Year Sharpe Ratio | -0.03 | ||
| 3-Year Sortino Ratio | -0.06 | ||
| Volatility % | 179.91 | ||
| 14-Day RSI | 38.95 | ||
| 14-Day ATR ($) | 1.232674 | ||
| 20-Day SMA ($) | 17.637 | ||
| 12-1 Month Momentum % | 239.81 | ||
| 52-Week Range ($) | 3.02 - 30 | ||
| Shares Outstanding (Mil) | 1.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Galera Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Galera Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 122 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 30 days | ||
| 0.005:1 Stock Split | 2026-07-13 | 17.60 (-1.12%) | ||
| First quarter earnings results for 2026 | 2026-05-15 | 20.00 (+0.00%) | ||
| General meeting for 2026 | 2026-05-08 10:00 | 20.00 (+0.00%) | ||
| Annual report for 2025 | 2026-03-19 | 10.00 (+11.11%) | ||
| Third quarter earnings results for 2025 | 2025-11-13 | 4.70 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-13 | 4.65 (-5.10%) | ||
| First quarter earnings results for 2025 | 2025-05-15 | 4.81 (+1.26%) | ||
| Annual report for 2024 | 2025-03-31 | 6.50 (+0.00%) |
Show
Entries
Galera Therapeutics Inc Frequently Asked Questions
What is Galera Therapeutics Inc(GRTXD)'s stock price today?
The current price of GRTXD is $15.74. The 52 week high of GRTXD is $30.00 and 52 week low is $3.02.
When is next earnings date of Galera Therapeutics Inc(GRTXD)?
The next earnings date of Galera Therapeutics Inc(GRTXD) is 2026-08-13 Est..
Does Galera Therapeutics Inc(GRTXD) pay dividends? If so, how much?
Galera Therapeutics Inc(GRTXD) does not pay dividend.
Guru Commentaries on OTCPK:GRTXD
No articles.
Press Release
| Subject | Date | ||
|---|---|---|---|
| Thinking about buying stock in Prelude Therapeutics, Miniso Group, Galera Therapeutics, Spruce Biosciences, or Purple Innovation? | 2021-12-21 |
Articles on Galera Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers